We report 422 patients transplanted for light chain amyloidosis. Day-100 all-cause mortality has fallen from 12% prior to 1 January 2006 to 7% after 1 January 2006 (p = 0.09). Survival at 2 years has likewise improved from 78 to 82%. Serum troponin T and NT-proBNP were the only predictors of early mortality. Refined patient selection has improved the safety margin for patients undergoing high-dose therapy, and therapy-related mortality has been reduced by 40%.
ASJC Scopus subject areas
- Internal Medicine